- $151.73m
- $119.41m
- $118.71m
Brief: Assertio Holdings, Inc. Q3 Adjusted EPS USD 0.18 Vs. IBES Estimate USD -0.07
Brief: Assertio Announces Leadership Transition
Brief: FDA Says Assertio Specialty Pharmaceuticals Discontinues Manufacturing Of Otrexup, Injection
Assertio Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
Pharma firm Assertio Q2 adjusted core profit beats estimates
Assertio Holdings Inc expected to post a loss of 8 cents a share - Earnings Preview
Assertio Holdings Inc expected to post a loss of 8 cents a share - Earnings Preview
Assertio Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
Assertio Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Assertio Therapeutics to pay $3.6mln over alleged fentanyl product marketing violations, US DOJ says
Assertio Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview
Assertio Holdings Inc reports results for the quarter ended December 31 - Earnings Summary
Assertio Holdings Inc expected to post a loss of 4 cents a share - Earnings Preview
Assertio Holdings Inc expected to post a loss of 4 cents a share - Earnings Preview
Assertio Holdings Inc reports results for the quarter - Earnings Summary
Brief: Buxton Helmsley Calls On Assertio Board To Release Full Investigation Report
Assertio Holdings Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Buxton Helmsley Inverted Long Equity Position Into Short Interest In Assertio
Assertio Holdings Inc reports results for the quarter ended in June - Earnings Summary